{"id":"prandial-insulin-lispro","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Weight gain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin lispro is a recombinant human insulin analog created by reversing two amino acids (lysine and proline) at positions 28 and 29 of the B chain, which reduces self-association and enables faster absorption from subcutaneous injection sites compared to regular human insulin. It mimics the body's natural postprandial (mealtime) insulin response by rapidly lowering blood glucose levels. The drug is used to improve glycemic control in patients with diabetes mellitus by facilitating cellular glucose uptake and storage.","oneSentence":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood sugar levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:05.862Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02556840","phase":"NA","title":"Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-04-25","conditions":"Maturity-Onset Diabetes of the Young","enrollment":46},{"nctId":"NCT06280703","phase":"PHASE1","title":"A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-05-15","conditions":"Healthy, Type 1 Diabetes Mellitus","enrollment":118},{"nctId":"NCT06445946","phase":"PHASE4","title":"DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-08-01","conditions":"Gestational Diabetes Mellitus, Pregnancy, High Risk","enrollment":1572},{"nctId":"NCT04124302","phase":"PHASE4","title":"The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal.","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2019-10-01","conditions":"Diabetes Mellitus, Type 1","enrollment":76},{"nctId":"NCT05463744","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-08-12","conditions":"Type 1 Diabetes, Diabetes","enrollment":692},{"nctId":"NCT03087032","phase":"PHASE4","title":"Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2019-01-10","conditions":"Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)","enrollment":164},{"nctId":"NCT06419777","phase":"NA","title":"Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2024-09-01","conditions":"Gestational Diabetes, Pregnancy Related","enrollment":430},{"nctId":"NCT01524705","phase":"PHASE4","title":"FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-08","conditions":"Type 2 Diabetes","enrollment":102},{"nctId":"NCT04019821","phase":"PHASE4","title":"Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2020-01-01","conditions":"Diabetes Mellitus, Type 1","enrollment":72},{"nctId":"NCT04079881","phase":"PHASE1, PHASE2","title":"Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2020-02-13","conditions":"Type 1 Diabetes, Hyperglycemia, Postprandial","enrollment":1},{"nctId":"NCT04816890","phase":"PHASE2","title":"A Trial to Assess the Efficacy and Safety of M1 Pram P037 Prandial Insulin in Subjects With Type 1 Diabetes (T1DM)","status":"COMPLETED","sponsor":"Adocia","startDate":"2021-03-23","conditions":"Type 1 Diabetes Mellitus","enrollment":80},{"nctId":"NCT03234491","phase":"PHASE1","title":"Improving Post-Prandial Blood Glucose Control With Afrezza During Closed-Loop Therapy","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-11-22","conditions":"Post-Prandial Hyperglycemia, Post-Prandial Hypoglycemia","enrollment":15},{"nctId":"NCT01945099","phase":"EARLY_PHASE1","title":"Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy","status":"COMPLETED","sponsor":"Yale University","startDate":"2013-09","conditions":"Type 1 Diabetes","enrollment":13},{"nctId":"NCT04972175","phase":"PHASE1","title":"Safety and Efficacy of BC LisPram","status":"UNKNOWN","sponsor":"Michael Tsoukas","startDate":"2021-07-28","conditions":"Type1 Diabetes Mellitus","enrollment":16},{"nctId":"NCT04031599","phase":"NA","title":"Assessment of the Efficacy of the Artificial Pancreas Combined With a Qualitative Meal Size Estimation to Control Postprandial Glucose Levels","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2020-07-10","conditions":"Type 1 Diabetes","enrollment":30},{"nctId":"NCT03740919","phase":"PHASE3","title":"A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-07","conditions":"Type 1 Diabetes Mellitus","enrollment":751},{"nctId":"NCT04965051","phase":"NA","title":"Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-08","conditions":"Type 1 Diabetes Mellitus With Diabetic Gastroparesis, HbA1c, Time in Range","enrollment":40},{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258},{"nctId":"NCT03214367","phase":"PHASE3","title":"A Study of LY900014 in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-07-17","conditions":"Type 1 Diabetes Mellitus","enrollment":1392},{"nctId":"NCT03214380","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-07-14","conditions":"Type 2 Diabetes Mellitus","enrollment":933},{"nctId":"NCT01621178","phase":"PHASE3","title":"A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Type 2 Diabetes, Chronic Kidney Disease","enrollment":577},{"nctId":"NCT02152384","phase":"PHASE1","title":"A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-06","conditions":"Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT01194245","phase":"PHASE2","title":"Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2010-08","conditions":"Diabetes Mellitus, Type 1","enrollment":135},{"nctId":"NCT02197520","phase":"PHASE1","title":"A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-07","conditions":"Diabetes Mellitus, Type 2","enrollment":24},{"nctId":"NCT03102476","phase":"NA","title":"Environmental Effects Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Hull","startDate":"2016-06","conditions":"Type1diabetes","enrollment":10},{"nctId":"NCT02794155","phase":"PHASE2","title":"Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1)","status":"COMPLETED","sponsor":"Diasome Pharmaceuticals","startDate":"2016-06","conditions":"Type 1 Diabetes Mellitus","enrollment":157},{"nctId":"NCT01662921","phase":"PHASE2","title":"Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes","status":"COMPLETED","sponsor":"Sansum Diabetes Research Institute","startDate":"2013-04","conditions":"Diabetes During Pregnancy","enrollment":17},{"nctId":"NCT01269047","phase":"PHASE4","title":"Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2009-08","conditions":"Type 1 Diabetes","enrollment":37},{"nctId":"NCT02276859","phase":"PHASE4","title":"Normal Versus Dual Wave Insulin Bolus for High-protein Food","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2014-10","conditions":"Type 1 Diabetes","enrollment":70},{"nctId":"NCT01035801","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Insulin (IN-105) in Type 1 Diabetes Patients","status":"TERMINATED","sponsor":"Biocon Limited","startDate":"2010-08-21","conditions":"Type 1 Diabetes Mellitus","enrollment":20},{"nctId":"NCT02294474","phase":"PHASE3","title":"Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":505},{"nctId":"NCT02273180","phase":"PHASE3","title":"Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-10","conditions":"Type 1 Diabetes Mellitus","enrollment":507},{"nctId":"NCT02451917","phase":"PHASE4","title":"Glargine Versus NPH in Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2013-12","conditions":"Type 2 Diabetes Mellitus, Chronic Kidney Disease","enrollment":34},{"nctId":"NCT02490098","phase":"PHASE2","title":"Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2018-01","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT02915250","phase":"PHASE1","title":"A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Adocia","startDate":"2016-10","conditions":"Type 2 Diabetes Mellitus","enrollment":36},{"nctId":"NCT01810952","phase":"PHASE4","title":"The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2010-09","conditions":"Hyperglycemia, Diabetes Mellitus","enrollment":37},{"nctId":"NCT02739906","phase":"PHASE1, PHASE2","title":"A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM","status":"COMPLETED","sponsor":"Adocia","startDate":"2016-04","conditions":"Type 1 Diabetes Mellitus","enrollment":36},{"nctId":"NCT02685449","phase":"PHASE4","title":"Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps.","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2016-02","conditions":"Diabetes type1","enrollment":70},{"nctId":"NCT02416765","phase":"PHASE2","title":"Closed-loop Control of Postprandial Glucose Levels in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2015-05","conditions":"Type 1 Diabetes","enrollment":15},{"nctId":"NCT01110746","phase":"PHASE3","title":"To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy","status":"COMPLETED","sponsor":"Biodel","startDate":"2010-02","conditions":"Type 1 Diabetes Mellitus","enrollment":20},{"nctId":"NCT01000922","phase":"PHASE2","title":"A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro","status":"COMPLETED","sponsor":"Biodel","startDate":"2006-06","conditions":"Diabetes Mellitus","enrollment":24},{"nctId":"NCT01686620","phase":"PHASE2","title":"A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)","status":"COMPLETED","sponsor":"Biodel","startDate":"2012-08","conditions":"Type 1 Diabetes Mellitus","enrollment":132},{"nctId":"NCT00883558","phase":"PHASE2","title":"Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2009-05","conditions":"Diabetes Mellitus, Type 1","enrollment":48},{"nctId":"NCT01194258","phase":"PHASE2","title":"Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2010-08","conditions":"Diabetes Mellitus, Type II","enrollment":132},{"nctId":"NCT01159938","phase":"PHASE4","title":"A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-10","conditions":"Diabetes Mellitus, Type 2","enrollment":72},{"nctId":"NCT01175824","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-04","conditions":"Diabetes Mellitus, Type 2","enrollment":478},{"nctId":"NCT01621776","phase":"NA","title":"Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia","status":"COMPLETED","sponsor":"University of Florida","startDate":"2011-06","conditions":"Type 1 Diabetes","enrollment":107},{"nctId":"NCT01121835","phase":"PHASE4","title":"Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-02","conditions":"Diabetes Mellitus, Type 2","enrollment":934},{"nctId":"NCT01406496","phase":"NA","title":"Best Timing of Insulin Bolus Before Meals of Different Contents","status":"UNKNOWN","sponsor":"Kaplan Medical Center","startDate":"2011-08","conditions":"Type 1 Diabetes Mellitus","enrollment":24},{"nctId":"NCT00841919","phase":"PHASE4","title":"Insulin Therapy in the Hospital Comparing Two Protocols","status":"COMPLETED","sponsor":"Cook County Health","startDate":"2006-12","conditions":"Diabetes Mellitus, Type 2","enrollment":60},{"nctId":"NCT00356421","phase":"PHASE4","title":"A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®","status":"TERMINATED","sponsor":"Pfizer","startDate":"2006-11","conditions":"Diabetes Mellitus, Type 1","enrollment":58},{"nctId":"NCT00110370","phase":"PHASE4","title":"Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-04","conditions":"Diabetes Mellitus, Type 2","enrollment":300}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"INSULIN AUTOIMMUNE SYNDROME"},{"count":1,"reaction":"TYPE 1 DIABETES MELLITUS"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Humalog","LY275585"],"phase":"marketed","status":"active","brandName":"Prandial Insulin Lispro","genericName":"Prandial Insulin Lispro","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood sugar levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}